Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Net Margin (2021 - 2024)

Amylyx Pharmaceuticals has reported Net Margin over the past 4 years, most recently at 41542.61% for Q4 2024.

  • Quarterly results put Net Margin at 41542.61% for Q4 2024, down 4155389.0% from a year ago — trailing twelve months through Sep 2025 was 23974.06% (down 2382010.0% YoY), and the annual figure for FY2024 was 0.02%, down 1393.0%.
  • Net Margin for Q4 2024 was 41542.61% at Amylyx Pharmaceuticals, down from 17476.92% in the prior quarter.
  • Over the last five years, Net Margin for AMLX hit a ceiling of 587.43% in Q4 2022 and a floor of 41542.61% in Q4 2024.
  • Median Net Margin over the past 4 years was 134.01% (2024), compared with a mean of 7597.12%.
  • Biggest five-year swings in Net Margin: surged 985234bps in 2023 and later plummeted -4155389bps in 2024.
  • Amylyx Pharmaceuticals' Net Margin stood at 8120.0% in 2021, then surged by 107bps to 587.43% in 2022, then crashed by -98bps to 11.28% in 2023, then crashed by -368546bps to 41542.61% in 2024.
  • The last three reported values for Net Margin were 41542.61% (Q4 2024), 17476.92% (Q3 2024), and 7106.55% (Q2 2024) per Business Quant data.